Median (IQR) D-dimer levels for patients on VKAs compared with those on DOACs
| Drugs . | D-dimer (μg/L) . | ||||
|---|---|---|---|---|---|
| VKAs (n = 33) . | Apixaban (n = 37) . | Rivaroxaban (n = 34) . | Dabigatran (n = 30) . | Edoxaban (n = 30) . | |
| Trough | 219 (174-385)† | 290 (163-383)†† | 201 (98-322) | 220 (158-449)† | |
| Peak | 225 (158-343)∗,† | 263 (200-430)†† | 169 (140-296) | 201 (152-445)∗,† | |
| VKAs | 149 (117-270) | ||||
| Drugs . | D-dimer (μg/L) . | ||||
|---|---|---|---|---|---|
| VKAs (n = 33) . | Apixaban (n = 37) . | Rivaroxaban (n = 34) . | Dabigatran (n = 30) . | Edoxaban (n = 30) . | |
| Trough | 219 (174-385)† | 290 (163-383)†† | 201 (98-322) | 220 (158-449)† | |
| Peak | 225 (158-343)∗,† | 263 (200-430)†† | 169 (140-296) | 201 (152-445)∗,† | |
| VKAs | 149 (117-270) | ||||
Blood samples were collected in 1:10 volume of trisodium citrate, centrifuged for 20 minutes at 3000g and plasma aliquoted in capped plastic tubes, immediately frozen and stored at −70°C for later testing that was performed within 6 months. To limit methodological variability, the same number of plasma samples from patients on different types of anticoagulants was included in each session. D-dimer was measured with HSD-dimer on ACLTOP (Werfen Bedford, MA).
IQR, interquartile range.
P < .05, trough-vs-peak (paired data [Wilcoxon].
P < .05.
P < .01, trough or peak-vs-VKAs [unpaired data, Mann-Whitney]).